Diabetes and vascular disease. Pathophysiology, clinical consequences, and medical therapy: Part I

Circulation

Volumn 108, Issue 12, 2003, Pages 1527-1532

  Creager, Mark A ^a,c   Lüscher, Thomas F ^d   Cosentino, Francesco ^b   Beckman, Joshua A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d NONE

Author keywords

Atherosclerosis; Caldiovascular diseases; Diabetes mellitus; Insulin; Nitric oxide

Indexed keywords

FATTY ACID; GLUCOSE; INSULIN; NITRIC OXIDE; VASOCONSTRICTOR AGENT;

ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; DIABETES MELLITUS; DIABETIC ANGIOPATHY; ENDOTHELIUM CELL; FATTY ACID METABOLISM; HYPERGLYCEMIA; INSULIN RESISTANCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOSIS; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ARTERIOSCLEROSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; FATTY ACIDS, NONESTERIFIED; HUMANS; HYPERGLYCEMIA; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; THROMBOSIS; VASCULAR DISEASES; VASOCONSTRICTOR AGENTS;

EID: 0141615827     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000091257.27563.32     Document Type: Review

References (101)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997:14(suppl 5):S1-S85.
2. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-1200.
3. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol. 2001;12:383-389.
4. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-2012.
5. Radomski MW, Palmer RM, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun. 1987;148:1482-1489.
6. Sarkar R, Meinberg EG, Stanley JC, et al. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res. 1996;78:225-230.
7. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyle adhesion. Proc Natl Acad Sci USA. 1991;88: 4651-4655.
8. Zeiber AM, Fisslthaler B, Schras-Utz B, et al. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res. 1995;76:980-986.
9. Libby P. Changing concepts of atherogenesis. J Intern Med. 2000;247: 349-358.
10. Nomura S, Shouzu A, Omoto S, et al. Significance of chemokines and activated platelets in patients with diabetes. Clin Exp Immunol. 2000; 121:437-443.
11. Mohamed AK, Bierhaus A, Schiekofer S, et al. The role of oxidative stress and NF-kappaB activation in late diabetic complications. Biofactors. 1999;10:157-167.
12. Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest. 2001;107:255-264.
13. Tesfamariam B, Brown ML, Deykill D, et al. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J Clin Invest. 1990;85:929-932.
14. Bohlen HG. Lash JM. Topical hyperglycemia rapidly suppresses EDRF-mediated vasodilation of normal rat arterioles. Am J Physiol. 1993;265: H219-H225.
15. Meraji S, Jayakody L, Senaratne MP, et al. Endothelium-dependent relaxation in aorta of BB rat. Diabetes. 1987;36:978-981.
16. Pieper GM, Meier DA, Hager SR. Endothelial dysfunction in a model of hyperglycemia and hyperinsulinemia. Am J Physiol. 1995;269: H845-H850.
17. Johnstone MT, Creager SJ, Scales KM, et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus, Circulation. 1993;88:2510-2516.
18. Williams, SB, Cusco JA, Roddy MA, et al. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1996;27:567-574.
19. Clarkson P, Celermajer DS, Donald AE, et al. Impaired vascular reactivity in Insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol. 1996:28:573-579.
20. McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1992;35:771-776.
21. Arnal JF, Dinh-Xuan AT. Pueyo M, et al. Endothelium-derived nitric oxide and vascular physiology and pathology. Cell Mol Life Sci. 1999; 55:1078-1087
22. Cosentino F, Hishikawa K, Katusic ZS, et al. High glucose increases nitric oxide synthase expression and supemxide anion generation in human aortic endothelial cells. Circulation. 1997;96:25-28.
23. King GL. The role of hyperglycaemia and hyperinsulinaemia in causing vascular dysfunction in diabetes. Ann Med. 1996;28:427-432.
24. Kaiser N, Sasson S, Feener EP, et al. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes. 1993;42:80-89.
25. Tesfamariam B, Brown ML, Cohen RA. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin, Invest. 1991;87:1643-1648.
26. Williams, SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation, 1998;97:1695-1701.
27. Beckman JA, Goldfine AB, Gordon MB, et al. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation 2001;103:1618-1623.
28. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787-790.
29. Hink U, Li H. Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes, mellitus. Circ Res. 2001;88:E14-E22.
30. O. Cosentino F, Eto M, De Paolis P, et al. High glucose causes upregulation of cyclooxygenase-2 and alters, prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation. 2003;107:1017-1023.
31. Guzik TJ, Mussa S, Gastaldi D, et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation. 2002;105: 1656-1662.
32. Koppenol WH, Moreno JJ, Pryor WA, et al. Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide. Chem Res Toxicol. 1992;5:834-842.
33. Laursen JB, Somers M, Kurz S, et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation. 2001;103:282-1288.
34. Milstien S, Katusic Z. Oxidation of tetrahydrobiopterin by peroxynorite: implications for vascular endothelial function. Biochem Biophys Res Comm. 1999;263:681-684.
35. Wever RM, Luscher TF, Cosemtho F, et al. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation. 1998;97: 108-112.
36. Schmidt AM, Yan SD, Wautier JL, et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 1999;84:489-497.
37. Schmidt AM, Hori O, Brett J, et al. Cellular receptors for advanced glycation end products: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb. 1994;14:1521-1528.
38. Schmidt AM, Stern D. Atheroscler and diabetes, the RAGE connection. Curr Atheroscler Rep. 2000;2:430-436.
39. Tan KC, Chow WS, Ai VH, et al. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care. 2002;25: 1055-1059.
40. Wautier MP, Chappey O, Corda S, et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab. 2001;280:E685-E694.
41. Du XL, Edelstein D, Dimmeler S, et al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest. 2001;108:1341-1348.
42. Desco MC, Asensi M, Marquez R, et al. Xanthine oxidase is involved in free radical production in type I diabetes: protection by allopurinol. Diabetes. 2002;51:1118-11124.
43. Lin KY, Ito A, Asagami T, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation. 2002:106:987-992.
44. Jackson TS, Xu A, Vita JA, et al. Ascorbate prevents the interaction of superoxide and nitric oxide only at very high physiological concentrations. Circ Res. 1998;83:916-922.
45. Timimi FK, Ting HH, Haley EA, et al. Vitamin C improves endothelium-dependent vasodilation in patient, with insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1999;31:552-557.
46. Ting HH, Timimi FK, Boles KS, et al. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 1996;97:22-28.
47. Xia P, Inoguchi T, Kern TS, et al. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes. 1994;43:1122-1129.
48. Inoguchi T, Xia P, Kunisaki M, et al. Insulin's effect on protein kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues. Am J Physiol. 1994;267:E369-E379.
49. Beckman JA, Goldfine AB, Gordon MB, et al. Inhibition of protein kinase C beta prevents impaired edothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res. 2002;90:107-111.
50. Boden G. Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Proc Assoc Am Physicians. 1999;111:241-248.
51. Fujimoto WY. The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus. Am J Med. 2000; 108(suppl 6a):9S-14S.
52. Keley DE, Simoneau JA. Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. J Clin Invest. 1994; 94:2349-2356.
53. Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest. 1999;103:253-259.
54. Dichtl W, Nilsson L, Goncalves I, et al. Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells. Circ Res. 1999;84: 1085-1094.
55. Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes, 2000;49:1939-1945.
56. Steinberg HO, Tarshoby M, Monestel R, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest. 1997;100:1230-1239.
57. Pleiner J, Schaller G, Mittermayer F, et al. FFA-induced endothelial dysfunction can be corrected by vitamin C. J Clin Endocrinol Metab. 2002;87:2913-2917.
58. Griffin ME, Marcucci MJ, Cline GW, et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade, Diabetes. 1999;48: 270-1274.
59. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipopmteinemia in type 2 diabetes mellitus. Ann Intern Med. 2001;135:447-459.
60. Cummings MH, Watts GF, Umpleby AM, et al. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetologia. 1995;38:959-967.
61. Sniderman A, Thomas D, Marpole D, et al. Low density lipoprotein: a metabolic pathway for return of cholesterol to the splanchnic bed. J Clin Invest. 1978;61:867-873.
62. Dimitriadis E, Griffin M, Owens D, et al. Oxidation of low-density lipoprotein in NIDDM: its relationship to fatty acid composition. Diabetologia. 1995;38:1300-1306.
63. de Man FH, Weverling-Rijnshurger AW, van der Laarse A, et al. Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation: reversal after lipid-lowering therapy by atorvastatin. Arterioscler Thromb Vasc Biol. 2000;20:744-750.
64. Kuhn FE, Mohler ER, Satler LF, et al. Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. Am J Cardiol. 1991;68:1425-1430.
65. Zeng G. Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin: direct measurement in vascular endothelial cells. J Clin Invest. 1996;98:894-898.
66. Kuboki K, Jiang ZY, Takahara N, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation. 2000;101:676-681.
67. Zeng G, Nystrom FH, Ravichandran LV, et al. Roles for insulin receptor, P13-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000;101:1539-1545.
68. Laakso M, Edelman SV, Brechtel G, et al. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man: a novel mechanism for insulin resistance. J Clin Invest. 1990;85:1844-1852.
69. Mather K, Laakso M, Edelman S, et al. Evidence for physilogical coupling of insulin-mediated glucose metabolism and limb blood flow. Am J Physiol Endocrinol Metab. 2000;279:E1264-E1270.
70. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001;37: 1344-1350.
71. Watanabe Y, Sunayama S, Shimada K, et al. Troglitazone improves endothelial dysfunction in patients with insulin resistance. J Atheroscler Thromb. 2000;7:159-163.
72. Montagnani M, Golovchenko I, Kim I, et al. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem. 2002;277:1794-1799.
73. Oliver FJ, de la Rubia G, Feener EP, et al. Stimulation of endothelin-1 gene expression by insulin in endothelial cells. J Biol Chem. 1991;266: 23251-23256.
74. Ferri C, Pittoni V, Piecoli A, et al. Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J Clin Endocrinol Metab. 1995;80:829-835.
75. de Souza CJ, Eckhardt M, Gagen K, et al. Effects of pioglitazone on adipose tissue remodeling within the setting of ohesity and insulin resistance, Diabetes. 2001;50:1863-1871.
76. Kusunoki M, Hara T, Tsutsumi K, et al. The lipoprotein lipase activator, NO-1886, suppresses fat accumulation and insulin resistance in rats fed a high-fat diet. Diabetologia. 2000;43:875-880.
77. De Vriese AS, Verbeuren TJ, Van de Voorde J, et al. Endothelial dysfunction in diabetes. Br J Pharmacol. 2000;130:963-974.
78. Luft FC. Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases. Curr Opin Nephrol Hypertens. 2002;11:59-66.
79. Golovehenko I, Goalstone ML, Watson P, et al. Hyperinsulinemia enhances transcriptional activity of nuclear factor-kappaB induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells. Circ Res. 2000;87:746-752.
80. O'Driscoll G, Green D, Rankin J, et al. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest. 1997;100:678-684.
81. Hopfner RL, Gopalakrishnan V. Endothelin: emerging role in diabetic vascular complications. Diabetologia. 1999;42:1383-1394.
82. Piatti PM, Monti LD, Conti M, et al. Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes. 1996;45:316-321.
83. Wolpen HA, Steen SN, Istfan NW, et al. Insulin modulates circulating endothelin-1 levels in humans. Metabolism. 1993;42:1027-1030.
84. Cardillo C, Nambi SS, Kilcoyne CM, et al. Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation. 1999;100:820-825.
85. Cardillo C, Campia U, Bryant MB, et al. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation. 2002;106:1783-1787.
86. Nugent AG, McGurk C, Hayes JR, et al. Impaired vasoconstriction to endothelin 1 in patients with NIDDM. Diabetes. 1996;45:105-107.
87. McDaid EA, Monaghan B, Parker AI, et al. Peripheral autonomic impairment in patients newly diagnosed with type II diabetes. Diabetes Care. 1994;17:1422-1427.
88. Hattori Y, Hattori S, Sato N, et al. High-glucose-induced nuclear factor kappaB activation in vascular smooth muscle cells. Cardiovasc Res. 2000;46:188-197.
89. Suzuki LA, Poot M, Gerrity RG, et al. Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis: lack of direct growth-promoting effects of high glucose levels. Diabetes. 2001;50:851-860.
90. Fukumoto H, Naito Z, Asano G, et al. Immunohistochemical and morphometric evaluations of coronary atherosclerotic plaques associated with myocardial infarction and diabetes mellitus. J Atheroscler Thromb. 1998;5:29-35.
91. Hussain MJ, Peakman M, Gallati H, et al. Elevated serum levels of macrophage derived cytokines precede and accompany the onset of IDDM. Diabetologia. 1996;39:60-69
92. Uemura S, Matsushita H, Li W, et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res. 2001;88:1291-1298.
93. Vinik AI, Erbas T, Park TS, et al. Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001;24:1476-1485.
94. Assert R, Scherk G, Bumbure A, et al. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia. 2001;44:188-195.
95. Li Y, Woo V, Bose R. Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol. 2001;280:H1480-H1489.
96. Hafer-Macko CE, Ivey FM, Gyure KA, et al. Thrombomodulin deficiency in human diabetic nerve microvasculature. Diabetes. 2002;51: 1957-1963.
97. Ceriello A, Giacomello R, Stel G, et al. Hyperglycemiu-induced thrombin formation in diabetes: the possible role of oxidative stress. Diabetes. 1995;44:924-928.
98. Ceriello A, Giugliano D, Quatraro A, et al. Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans. Diabetologia. 1990;33:163-167.
99. Ren S, Lee H, Hu L, et al. Impact of diabetes-associated lipoproteins on generation of fibrinolytic regulators from vascular endothelial cells. J Clin Endocrinol Metab. 2002;87:286-291.
100. Kario K, Matsuo T, Kobayashi H, et al. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in noa-insulin-dependent diabetic patients with microalhuminuria. Arterioscler Thromb Vasc Biol. 1995;15:1114-1120.
101. Pandolfi A, Cetrullo D, Polishuck R, et al. Plasminogen activator inhibitor type 1 is increased in the arterial wall of type 11 diabetic subjects. Arterioscler Thromb Vasc Biol. 2001;21:1378-1382.